195 related articles for article (PubMed ID: 7086136)
21. Presence of a macrophage-mediated suppressor cell mechanism during cell-mediated immune response in experimental visceral leishmaniasis.
Murray HW; Carriero SM; Donelly DM
Infect Immun; 1986 Nov; 54(2):487-93. PubMed ID: 2945788
[TBL] [Abstract][Full Text] [Related]
22. Relationship between parasite load and immune responses in early stages of Leishmania donovani infection in inbred BALB/c mice.
Wahinya DN; Mbati PA; Jomo PM; Githure JI
East Afr Med J; 1998 Mar; 75(3):156-9. PubMed ID: 9640813
[TBL] [Abstract][Full Text] [Related]
23. Non PC liposome entrapped promastigote antigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis.
Sharma SK; Dube A; Nadeem A; Khan S; Saleem I; Garg R; Mohammad O
Vaccine; 2006 Mar; 24(11):1800-10. PubMed ID: 16310900
[TBL] [Abstract][Full Text] [Related]
24. Lack of CXCR3 delays the development of hepatic inflammation but does not impair resistance to Leishmania donovani.
Barbi J; Oghumu S; Rosas LE; Carlson T; Lu B; Gerard C; Lezama-Davila CM; Satoskar AR
J Infect Dis; 2007 Jun; 195(11):1713-7. PubMed ID: 17471442
[TBL] [Abstract][Full Text] [Related]
25. Reversal of T-cell unresponsiveness through serine-esterase inhibitors mediated enhanced lymphokine induced microbicidal activities in kala-azar.
Bimal S; Lal SL; Lal CS; Singha UK; Saran R; Sen AB; Sahay VK
Indian J Exp Biol; 1992 Jan; 30(1):54-6. PubMed ID: 1506018
[TBL] [Abstract][Full Text] [Related]
26. Immunostimulant activity of a novel lipopeptide and its protective action against Leishmania donovani.
Puri A; Rizvi SY; Haq W; Guru PY; Kundu B; Saxena RP; Shukla R; Mathur KB; Saxena KC
Immunopharmacol Immunotoxicol; 1993 Nov; 15(5):539-56. PubMed ID: 8301018
[TBL] [Abstract][Full Text] [Related]
27. Visceral leishmaniasis: a disease associated with inability of lymphocytes to activate macrophages to kill leishmania.
Carvalho EM; Bacellar OA; Reed S; Barral A; Rocha H
Braz J Med Biol Res; 1988; 21(1):85-92. PubMed ID: 3179584
[TBL] [Abstract][Full Text] [Related]
28. Immunomodulatory activity of analog of muramyl dipeptide and their use as adjunct to chemotherapy of Leishmania donovani in hamster.
Puri A; Sahai R; Haq W; Zaidi A; Guru PY; Tripathi LM; Srivastava VM
Int Immunopharmacol; 2005 Jun; 5(6):937-46. PubMed ID: 15829410
[TBL] [Abstract][Full Text] [Related]
29. Presentation of the protective parasite antigen LACK by Leishmania-infected macrophages.
Prina E; Lang T; Glaichenhaus N; Antoine JC
J Immunol; 1996 Jun; 156(11):4318-27. PubMed ID: 8666803
[TBL] [Abstract][Full Text] [Related]
30. In experimental leishmaniasis deficiency of CD18 results in parasite dissemination associated with altered macrophage functions and incomplete Th1 cell response.
Schönlau F; Scharffetter-Kochanek K; Grabbe S; Pietz B; Sorg C; Sunderkötter C
Eur J Immunol; 2000 Sep; 30(9):2729-40. PubMed ID: 11009109
[TBL] [Abstract][Full Text] [Related]
31. Signaling events leading to the curative effect of cystatin on experimental visceral leishmaniasis: involvement of ERK1/2, NF-kappaB and JAK/STAT pathways.
Kar S; Ukil A; Das PK
Eur J Immunol; 2009 Mar; 39(3):741-51. PubMed ID: 19197936
[TBL] [Abstract][Full Text] [Related]
32. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
Datta N; Mukherjee S; Das L; Das PK
Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
[TBL] [Abstract][Full Text] [Related]
33. Transcriptional Profiling in Experimental Visceral Leishmaniasis Reveals a Broad Splenic Inflammatory Environment that Conditions Macrophages toward a Disease-Promoting Phenotype.
Kong F; Saldarriaga OA; Spratt H; Osorio EY; Travi BL; Luxon BA; Melby PC
PLoS Pathog; 2017 Jan; 13(1):e1006165. PubMed ID: 28141856
[TBL] [Abstract][Full Text] [Related]
34. Lymph node cells from BALB/c mice with chronic visceral leishmaniasis exhibiting cellular anergy and apoptosis: involvement of Ser/Thr phosphatase.
Mukherjee P; Sen PC; Ghose AC
Apoptosis; 2006 Nov; 11(11):2013-29. PubMed ID: 17013755
[TBL] [Abstract][Full Text] [Related]
35. Nature of resistance to leishmaniasis in experimental rodents.
Gorczynski RM
Dev Comp Immunol; 1982; 6(2):199-207. PubMed ID: 6807726
[No Abstract] [Full Text] [Related]
36. DNA vaccination against the parasite enzyme gamma-glutamylcysteine synthetase confers protection against Leishmania donovani infection.
Carter KC; Henriquez FL; Campbell SA; Roberts CW; Nok A; Mullen AB; McFarlane E
Vaccine; 2007 May; 25(22):4502-9. PubMed ID: 17418459
[TBL] [Abstract][Full Text] [Related]
37. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis.
Rachamim N; Jaffe CL
J Immunol; 1993 Mar; 150(6):2322-31. PubMed ID: 8450215
[TBL] [Abstract][Full Text] [Related]
38. Leishmania donovani vs immunity: T-cells sensitized from Leishmania of one donor may modulate their cytokines pattern on re-stimulation with Leishmania from different donor in visceral leishmaniasis.
Narayan S; Bimal S; Singh SK; Gupta AK; Singh VP; Sinha PK; Das P
Exp Parasitol; 2009 Jan; 121(1):69-75. PubMed ID: 18948098
[TBL] [Abstract][Full Text] [Related]
39. Responses to Leishmania donovani in mice deficient in both phagocyte oxidase and inducible nitric oxide synthase.
Murray HW; Xiang Z; Ma X
Am J Trop Med Hyg; 2006 Jun; 74(6):1013-5. PubMed ID: 16760512
[TBL] [Abstract][Full Text] [Related]
40. [Immunologic complications of visceral leishmaniasis].
Niggli F; Halle F; Seger RA
Monatsschr Kinderheilkd; 1991 Nov; 139(11):772-4. PubMed ID: 1775144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
